Welcome to our dedicated page for Protagonist Ther SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Protagonist Therapeutics’ (PTGX) filings—rich with peptide-science jargon, cash-runway disclosures, and collaboration milestones—can be overwhelming. Whether you’re scanning a sudden 8-K or tracing capital raises, the information you need hides in technical detail. That’s why investors search for “understanding Protagonist Therapeutics SEC documents with AI” and “Protagonist Therapeutics SEC filings explained simply.”
Stock Titan turns that challenge into clarity. Our platform delivers AI-powered summaries that highlight trial updates, partnership economics, and risk factors inside every Protagonist Therapeutics annual report 10-K simplified, each Protagonist Therapeutics quarterly earnings report 10-Q filing, and even the briefest Protagonist Therapeutics 8-K material events explained. Real-time alerts flag Protagonist Therapeutics Form 4 insider transactions real-time, so you never miss new Protagonist Therapeutics executive stock transactions Form 4. Need detail? Click into a filing and our expert notes walk you straight to cash-position tables, IL-23 program costs, or board-level pay disclosures from the Protagonist Therapeutics proxy statement executive compensation section.
Use these insights to act faster: compare revenue from milestone payments with R&D burn in our Protagonist Therapeutics earnings report filing analysis; monitor Protagonist Therapeutics insider trading Form 4 transactions ahead of data readouts; or archive every disclosure for audits. With comprehensive coverage of all forms—10-K, 10-Q, 8-K, S-3, Schedule 13G—and continuous EDGAR updates, Stock Titan equips you to follow this clinical-stage biotech’s journey from lab bench to commercial launch, without wading through hundreds of pages on your own.
Protagonist Therapeutics (PTGX)
Sales included 4,000 shares at $69.25 and 8,000 shares at a $87.81 weighted average, with individual trades ranging from $86.71 to $88.00. Following these transactions, he directly holds 5,130 shares. The exercised options were fully vested and were set to expire on 05/28/2028.
Protagonist Therapeutics, Inc. (PTGX) reported an insider notice to sell 12,000 common shares via Morgan Stanley Smith Barney on
Two prior 10b5-1 sales attributed to William Waddill are disclosed:
Protagonist Therapeutics director William D. Waddill sold 4,000 shares of Protagonist Therapeutics, Inc. (PTGX) common stock on 09/22/2025 at a price of $64.25 per share, leaving him with 5,130 shares beneficially owned following the transaction. The sale was executed under a Rule 10b5-1 trading plan that the reporting person adopted on November 10, 2023. The Form 4 was signed on behalf of Mr. Waddill by an attorney-in-fact on 09/24/2025. The filing reports the transaction as a non-derivative disposition by a director and indicates the Form was filed by one reporting person.
Form 144 notice for Protagonist Therapeutics, Inc. (PTGX) reports a proposed sale of 4,000 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $248,800 and an approximate sale date of 09/22/2025 on NASDAQ. The filer acquired the shares on 05/03/2022 via previously exercised stock options and paid cash. The filing also discloses a 10b5-1 sale by the same person of 4,000 shares on 08/27/2025 for gross proceeds of $237,000. The notice includes the seller’s representation about absence of undisclosed material adverse information.
Dinesh V. Patel, Ph.D., President and CEO and director of Protagonist Therapeutics, Inc. (PTGX), reported a change in beneficial ownership on Form 4. The filing discloses a transaction dated 09/16/2025 in which Dr. Patel made a bona fide gift of 620 shares of the issuer's common stock to his son at a reported price of $0 (coded G). After the reported transaction, Dr. Patel beneficially owned 519,983 shares, held directly. The Form 4 was signed on 09/18/2025 by Matthew Gosling as attorney-in-fact for Dr. Patel.
William D. Waddill, a director of Protagonist Therapeutics, Inc. (PTGX), sold 4,000 shares of common stock on 08/27/2025 at $59.25 per share under a Rule 10b5-1 trading plan adopted on November 10, 2023. After the sale he beneficially owns 9,130 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/29/2025, and the filing indicates the transaction was effected pursuant to the pre-established 10b5-1 plan.
Protagonist Therapeutics, Inc. (PTGX) filing of Form 144 notifies a proposed sale of 4,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 08/27/2025. The shares were acquired on 05/03/2022 via previously exercised stock options and paid in cash. The filing reports an aggregate market value of $227,960.00 for the shares to be sold and indicates 62,211,318 shares outstanding for the issuer. The filer certifies they are not aware of undisclosed material adverse information and states no sales by the filer in the past three months.
State Street Corporation filed a Schedule 13G reporting beneficial ownership of common stock of Protagonist Therapeutics, Inc. The filing states State Street beneficially owns 3,207,774 shares, representing 5.2% of the outstanding class. The report shows 0 shares as sole voting power and sole dispositive power, with 3,033,685 shares of shared voting power and 3,207,774 shares of shared dispositive power.
The filing lists several State Street entities through which the position is held, including SSGA Funds Management, Inc., State Street Bank and Trust Company, and multiple State Street Global Advisors entities. The submission includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
